TABLE 1.
Inhibitor | Inhibitor concn (μM) | % Inhibitiona by:
|
|
---|---|---|---|
ELISA | NERT | ||
NVP | 10 | 87 ± 12 | 77 ± 11 |
100 | 99 ± 2 | 100 | |
PFA | 30 | 98 ± 3 | 45 ± 5 |
300 | 98 ± 2 | 100 | |
PAA | 70 | 0 ± 1 | 0 |
700 | 9 ± 2 | 0 | |
2,800 | 42 ± 4 | 0 | |
ddATP | 10 | NTb | 71 ± 6 |
100 | NT | 100 | |
ddTTP | 10 | 99 ± 1 | 70 ± 5 |
100 | 100 | 100 | |
Ro 5-3335 | 20 | NT | 0 |
25 | 6 ± 5 | NT | |
200 | NT | 0 | |
250 | 19 ± 8 | NT | |
Ro 24-7429 | 20 | NT | 32 ± 9 |
25 | 62 ± 16 | NT | |
200 | NT | 56 ± 5 | |
250 | 84 ± 19 | NT | |
RA | 10 | 16 ± 3 | 26 ± 9 |
100 | 30 ± 7 | 44 ± 13 | |
200 | 50 ± 4 | 62 ± 4 | |
Curcumin | 12.5 | 18 ± 10 | 0 |
100 | 29 ± 12 | 0 | |
200 | 29 ± 13 | 0 | |
DMSO | ∼1% (vol/vol) | 0 | 0 |
Data are shown as average ± standard deviation from at least three separate experiments. Percent inhibition was calculated as 100(1 − Sn/S0), where Sn and S0 represent the PCR signals in the presence of n and 0 μM drug, respectively. Proximal or intermediate PCR primer pairs were used in all cases.
NT, not tested.